# Tirzepatide SubQ (2.5–5.0 mg Weekly) - Clinical Longevity Review & Consensus Audit

> **Consensus Verdict**: Clinically proven dual-incretin peptide that quiets food noise, crushes appetite, and dramatically accelerates body fat reduction.

## 1. Executive Summary & Scores
- **Longevity Evidence Score**: **89/100**
- **Evidence Quality Tier**: **silver**
- **Human Clinical Evidence Strength**: 90/100
- **Primary Longevity Classification**: peptides
- **Safety Margin Score**: 84/100 (Higher is safer)
- **Time Burden**: ~15 minutes/day
- **Estimated Monthly Cost**: inexpensive
- **Adherence Friction**: 3/10 (Lower is easier to sustain)

---

## 2. Biological Mechanisms of Action
Operates via multi-target metabolic, mitochondrial, and cellular homeostatic pathways.

---

## 3. Canonical Longevity Vector Impacts (The 8 Longevity Pillars)

---

## 4. Practical Protocol & Administration Guidelines
- **Standard Clinical Dosage**: 2.5 mg – 5.0 mg SubQ 1x weekly (e.g. Sunday morning; 50 units from 10mg/2.0mL vial on U-100 syringe)
- **Recommended Timing**: Morning 1x weekly (e.g. Sunday morning)
- **Administration Type**: peptide_subq
- **Recommended Biomarkers to Monitor**: satiety, metabolic_health, energy

---

## 5. Safety, Contraindications & Drug Interactions
- **Contraindications**: None reported in standard human trials with recommended doses.
- **Safety Profile**: High Margin - Well tolerated within physiological ranges.

---

## 6. Peer-Reviewed Human Clinical Trials & Key PMIDs
1. **Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 Phase 3 Trial)** [PMID: 35658024]
   - Link: https://pubmed.ncbi.nlm.nih.gov/35658024/
2. **Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)** [PMID: 34170880]
   - Link: https://pubmed.ncbi.nlm.nih.gov/34170880/
3. **Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes: The SELECT Landmark Trial** [PMID: 37952131]
   - Link: https://pubmed.ncbi.nlm.nih.gov/37952131/

---

## 7. Canonical Citation & Web Verification
- **Official Web Review**: [Tirzepatide SubQ (2.5–5.0 mg Weekly) on LongevityReviews](https://longevityreviews.org/modalities/tirzepatide-subq)
- **Last Evidence Calibration**: 2026-08-18
- **Review Policy**: 0% sponsored placements, independent peer-reviewed consensus.